Related references
Note: Only part of the references are listed.Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
Christiane R. Stadler et al.
ONCOIMMUNOLOGY (2016)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond
Britta Vallazza et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2015)
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer
Patrick Micke et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Bispecific antibodies rise again
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
mRNA-based therapeutics - developing a new class of drugs
Ugur Sahin et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Katalin Kariko et al.
NUCLEIC ACIDS RESEARCH (2011)
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Bart R. Anderson et al.
NUCLEIC ACIDS RESEARCH (2010)
Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
Ugur Sahin et al.
CLINICAL CANCER RESEARCH (2008)
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Katalin Kariko et al.
MOLECULAR THERAPY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
Silke Holtkamp et al.
BLOOD (2006)
Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA
K Karikó et al.
IMMUNITY (2005)
Share Paper
